

MIMS®: WHERE NOTHING GETS LEFT BEHIND

Introducing a stentless, simple, and rapid glaucoma treatment that effectively lowers IOP without invasive surgery

Despite its prevalence and impact on vision, there is no cure for glaucoma – but its progression can at least be proactively stalled. Indeed, by intervening early and quickly, we can reduce the risk of later complications. With this interventional mindset, Israeli ophthalmic medical device start-up company Sanoculis has developed Minimally Invasive Micro Sclerostomy or MIMS® – a MIGS procedure: an innovative minimally invasive surgical approach for the treatment of glaucoma. Bausch + Lomb and Sanoculis have recently entered into an exclusive agreement to distribute MIMS® in Europe.

MIMS® is a stentless, simple, and rapid glaucoma surgical treatment designed to effectively lower IOP without invasive surgery and without leaving an implant in the eye. An initial temporal peripheral corneal incision of 1.5 mm is made, through which the MIMS® specially designed single use device passes through, until its tip firmly touches the opposite eye-wall. Then, a small gauge, Micro-Trephine, automatically creates a channel from the anterior chamber through the sclera directly into the sub-conjunctival space, thereby bypassing the four areas of resistance: trabecular meshwork, Schlemm's canal, collector channels and uveal scleral outflow pathway.

This channel then remains open and aids drainage, effectively reducing IOP build up.

Who is MIMS® for?

MIMS® surgical procedure is indicated in phakic or pseudophakic patients for treatment of primary open-angle glaucoma (including pseudoexfoliation and pigmentary glaucoma), with an uncontrolled glaucoma (IOP of 21 mmHg or above on maximal tolerated medical therapy), Shaffer grade ≥ III (wide open angle) and mobile and elastic conjunctiva in the quadrant intended for surgery.

MIMS® is also suitable for combined cataract surgery. Chronic angle closure glaucoma patients are suitable for MIMS® only if they are pseudophakic or undergoing combined surgery.

MIMS® is a stentless, simple (short learning curve, no surgical gonioprism required), fast (average time 2 minutes 3 seconds (±43 seconds) (1)) procedure. Clinical outcomes from a 12-month follow-up study on 120 patients reported that MIMS® allows for effective IOP management in open angle glaucoma.

Expanded indications for MIMS®: clinical studies

Sanoculis is looking to expand indications for MIMS® to all glaucoma patients who need surgery.

MIMS® was successfully used for the inferonasal sclerostomy and nasal trabeculostomy on 15 patients for each indication in a pilot study with a three-month follow up (2). Thus, pivotal studies for CE mark approval have been initiated for each indication. Sixty-six patients will be enrolled and followed for six months after surgery. Completion of both clinical studies is expected late 2023.

MIMS® has received CE mark approval in the EU, but it is not yet approved in the US.



bauschsurgical.eu
BL_INNOADV_1222_



References

1. L. Voskanyan, "New arrival – a fresh approach to treating glaucoma." Presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.
2. Paper presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.

STUDY BY GLAUCOMA SPECIALISTS LILIT VOSKANYAN (ARMENIA) AND IKE AHMED (CANADA) (1)

Voskanyan and Ahmed and their teams looked at 100 standalone MIMS® cases and 20 cases combined with cataract surgery (109 MIMS® procedures performed by Voskanyan, 11 by Ahmed). They observed a 38-percent reduction in the IOP from baseline, with a reduction in medications of 85 percent after 12 months. No unexpected intra- or postoperative complications were reported.

